Vlad Coric

Insider Reports History

Reporting-owner location: New Haven, CT
Latest reporting-owner signature: /s/ Sean Weisberg, as Attorney-in-Fact for Vlad Coric
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Vlad Coric

Form 4 holding Chief Executive Officer, Director

Biohaven Pharmaceutical Holding Co Ltd.

Security class: Common Shares
Shares / value: 830,891
Estimated value: $123,387,314
Report date: 03 Oct 2022
Price: $148.50
Ownership: Direct

Form 4 holding Chief Executive Officer, Director

Biohaven Pharmaceutical Holding Co Ltd.

Security class: Common Shares
Shares / value: 517,391
Estimated value: $76,832,564
Report date: 03 Oct 2022
Price: $148.50
Ownership: By: The Vladimir Coric Marital Trust

Form 4 holding Chief Executive Officer, Director

Biohaven Pharmaceutical Holding Co Ltd.

Security class: Common Shares
Shares / value: 498,261
Estimated value: $73,991,759
Report date: 03 Oct 2022
Price: $148.50
Ownership: By 401(K) Plan

Form 4 holding Chief Executive Officer, Director

Biohaven Ltd.

Security class: Common Shares
Shares / value: 1,803,968
Estimated value: $17,913,402
Report date: 05 Jan 2026
Price: $9.93
Ownership: Direct

Form 4 holding Chief Executive Officer, Director

Biohaven Ltd.

Security class: Common Shares
Shares / value: 1,195,275
Estimated value: $13,494,654
Report date: 05 Jan 2026
Price: $11.29
Ownership: By: The Vlad Coric Family Trust

Form 4 holding Chief Executive Officer, Director

Biohaven Ltd.

Security class: Common Shares
Shares / value: 740,546
Estimated value: $8,360,764
Report date: 05 Jan 2026
Price: $11.29
Ownership: By: The Vladimir Coric Marital Trust

Form 4 holding Chief Executive Officer, Director

Biohaven Ltd.

Security class: Common Shares
Shares / value: 109,565
Estimated value: $1,236,988
Report date: 05 Jan 2026
Price: $11.29
Ownership: By: 401(K) Plan

Form 4 holding Director

Royalty Pharma plc

Security class: Class A Ordinary Shares
Shares / value: 15,343
Estimated value: $736,003
Report date: 05 Jun 2026
Price: $47.97
Ownership: Direct

Form 4 holding Director

Revance Therapeutics, Inc.

Security class: Common Stock
Shares / value: 0
Estimated value: $0
Report date: 06 Feb 2025
Price: $3.65
Ownership: Direct

Form 4 holding Chief Executive Officer, Director

Biohaven Ltd.

Security class: Stock Options (Right to buy)
Shares / value: 550,000
Estimated value
Report date: 27 Feb 2026
Price
Ownership: Direct
Underlying class: Common Shares
Underlying amount

Form 4 holding Director

Veradermics, Inc

Security class: Common Stock
Shares / value: 319,398
Estimated value
Report date: 05 Feb 2026
Price
Ownership: Indirect

Form 4 holding Director

Veradermics, Inc

Security class: Common Stock
Shares / value: 129,939
Estimated value
Report date: 05 Feb 2026
Price
Ownership: Direct

Form 4 holding Director

Veradermics, Inc

Security class: Stock Option (Right to Buy)
Shares / value: 51,525
Estimated value
Report date: 03 Feb 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Chief Executive Officer, Director

Biohaven Ltd.

Security class: Restricted Share Unit Award
Shares / value: 28,500
Estimated value
Report date: 05 Jan 2026
Price
Ownership: Direct
Underlying class: Common Shares
Underlying amount

Form 4 holding Director

Revance Therapeutics, Inc.

Security class: Stock Option (Right to buy)
Shares / value: 23,458
Estimated value
Report date: 01 May 2024
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Chief Executive Officer, Director

Biohaven Pharmaceutical Holding Co Ltd.

Security class: Common Shares
Shares / value: 0
Estimated value
Report date: 03 Oct 2022
Price: $148.50
Ownership: By: The Vladimir Coric Family Trust

Form 4 holding Chief Executive Officer, Director

Biohaven Pharmaceutical Holding Co Ltd.

Security class: Restricted Share Unit Award
Shares / value: 0
Estimated value
Report date: 03 Oct 2022
Price
Ownership: Direct
Underlying class: Common Shares
Underlying amount

Form 4 holding Chief Executive Officer, Director

Biohaven Pharmaceutical Holding Co Ltd.

Security class: Stock Options (Right to Buy)
Shares / value: 0
Estimated value
Report date: 03 Oct 2022
Price
Ownership: Direct
Underlying class: Common Shares
Underlying amount

Form 4 holding Director

Veradermics, Inc

Security class: Series A Convertible Preferred Stock
Shares / value: 0
Estimated value
Report date: 05 Feb 2026
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Veradermics, Inc

Security class: Series B Convertible Preferred Stock
Shares / value: 0
Estimated value
Report date: 05 Feb 2026
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Veradermics, Inc

Security class: Series C Convertible Preferred Stock
Shares / value: 0
Estimated value
Report date: 05 Feb 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Veradermics, Inc

Security class: Series C Convertible Preferred Stock
Shares / value: 0
Estimated value
Report date: 05 Feb 2026
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Vlad Coric

4 RPRX

Royalty Pharma plc

Report period: 05 Jun 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Jun 2026, 16:21
Role: Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 27 Feb 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 03 Mar 2026, 18:04
Role: Chief Executive Officer, Director
Next action: Open filing details

4 MANE

Veradermics, Inc

Report period: 03 Feb 2026
Transactions: 17
Transaction value: +$1,999,982
Accepted by SEC: 05 Feb 2026, 19:04
Role: Director
Next action: Open filing details

3 MANE

Veradermics, Inc

Report period: 03 Feb 2026
Transactions: 0
Transaction value: $0
Accepted by SEC: 03 Feb 2026, 21:05
Role: Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 05 Jan 2026
Transactions: 3
Transaction value: -$73,780
Accepted by SEC: 07 Jan 2026, 21:32
Role: Chief Executive Officer, Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 13 Nov 2025
Transactions: 2
Transaction value: +$4,999,995
Accepted by SEC: 17 Nov 2025, 07:30
Role: Chief Executive Officer, Director
Next action: Open filing details

4 RPRX

Royalty Pharma plc

Report period: 13 May 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 14 May 2025, 17:06
Role: Director
Next action: Open filing details

4 RPRX

Royalty Pharma plc

Report period: 21 Apr 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 21 Apr 2025, 17:43
Role: Director
Next action: Open filing details

3/A RPRX

Royalty Pharma plc

Report period: 07 Apr 2025
Transactions: 0
Transaction value: $0
Accepted by SEC: 21 Apr 2025, 17:40
Role: Director
Next action: Open filing details

Revance Therapeutics, Inc.

Report period: 04 Feb 2025
Transactions: 2
Transaction value: -$21,112
Accepted by SEC: 06 Feb 2025, 15:49
Role: Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 05 Jan 2025
Transactions: 5
Transaction value: -$262,945
Accepted by SEC: 07 Jan 2025, 20:48
Role: Chief Executive Officer, Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 02 Oct 2024
Transactions: 1
Transaction value: +$999,970
Accepted by SEC: 03 Oct 2024, 07:00
Role: Chief Executive Officer, Director
Next action: Open filing details

Revance Therapeutics, Inc.

Report period: 01 May 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 03 May 2024, 08:43
Role: Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 22 Apr 2024
Transactions: 1
Transaction value: +$4,999,991
Accepted by SEC: 23 Apr 2024, 07:54
Role: Chief Executive Officer, Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 05 Apr 2024
Transactions: 3
Transaction value: $0
Accepted by SEC: 05 Apr 2024, 20:21
Role: Chief Executive Officer, Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 08 Mar 2024
Transactions: 3
Transaction value: $0
Accepted by SEC: 08 Mar 2024, 18:35
Role: Chief Executive Officer, Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 08 Jan 2024
Transactions: 3
Transaction value: $0
Accepted by SEC: 10 Jan 2024, 21:11
Role: Chief Executive Officer, Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 02 Jan 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 04 Jan 2024, 20:07
Role: Chief Executive Officer, Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 02 Nov 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Nov 2023, 20:34
Role: Chief Executive Officer, Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 05 Oct 2023
Transactions: 2
Transaction value: +$9,999,990
Accepted by SEC: 10 Oct 2023, 07:17
Role: Chief Executive Officer, Director
Next action: Open filing details

Revance Therapeutics, Inc.

Report period: 03 May 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 05 May 2023, 17:14
Role: Director
Next action: Open filing details

Revance Therapeutics, Inc.

Report period: 01 Mar 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 03 Mar 2023, 15:32
Role: Director
Next action: Open filing details

Revance Therapeutics, Inc.

Report period: 01 Mar 2023
Transactions: 0
Transaction value: $0
Accepted by SEC: 03 Mar 2023, 15:31
Role: Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 31 Oct 2022
Transactions: 1
Transaction value: +$411,995
Accepted by SEC: 01 Nov 2022, 07:34
Role: Chief Executive Officer, Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 28 Oct 2022
Transactions: 2
Transaction value: +$2,105,772
Accepted by SEC: 31 Oct 2022, 07:52
Role: Chief Executive Officer, Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 25 Oct 2022
Transactions: 1
Transaction value: +$8,960,490
Accepted by SEC: 26 Oct 2022, 18:22
Role: Chief Executive Officer, Director
Next action: Open filing details

4 BHVN

Biohaven Ltd.

Report period: 05 Oct 2022
Transactions: 9
Transaction value: +$5,009,425
Accepted by SEC: 06 Oct 2022, 19:20
Role: Chief Executive Officer, Director
Next action: Open filing details

4/A BHVN

Biohaven Ltd.

Report period: 03 Oct 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 12 Oct 2022, 18:31
Role: Chief Executive Officer, Director
Next action: Open filing details

Biohaven Pharmaceutical Holding Co Ltd.

Report period: 03 Oct 2022
Transactions: 26
Transaction value: -$137,056,738
Accepted by SEC: 03 Oct 2022, 20:26
Role: Chief Executive Officer, Director
Next action: Open filing details

3 BHVN

Biohaven Ltd.

Report period: 22 Sep 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 28 Sep 2022, 20:51
Role: Chief Executive Officer, Director
Next action: Open filing details

Biohaven Pharmaceutical Holding Co Ltd.

Report period: 06 Jan 2022
Transactions: 8
Transaction value: -$1,322,260
Accepted by SEC: 07 Jan 2022, 20:16
Role: Chief Executive Officer, Director
Next action: Open filing details

Biohaven Pharmaceutical Holding Co Ltd.

Report period: 31 Dec 2021
Transactions: 4
Transaction value: $0
Accepted by SEC: 11 Feb 2022, 20:15
Role: Chief Executive Officer, Director
Next action: Open filing details

Biohaven Pharmaceutical Holding Co Ltd.

Report period: 25 Nov 2021
Transactions: 3
Transaction value: -$586,416
Accepted by SEC: 26 Nov 2021, 15:28
Role: Chief Executive Officer, Director
Next action: Open filing details

Social Capital Suvretta Holdings Corp. I

Report period: 29 Jun 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 29 Jun 2021, 20:06
Role: Director
Next action: Open filing details

Insider Reports History

Continue from this owner filing history

Reported holdings for Vlad Coric

Insider Reports Filed by Vlad Coric